Evidence map›Paper›PMID 33339135›Full record

ArticleCancers2020

The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies-Beyond

Gabriela Marsavela, Peter A Johansson, Michelle R Pereira, Ashleigh C McEvoy, Anna L Reid, Cleo Robinson, Lydia Warburton, Muhammad A Khattak, Tarek M Meniawy, Benhur Amanuel and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Circulating Tumor DNA as a Biomarker for Melanoma Prognosis and Therapy.American journal of clinical dermatology · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Circulating Tumour DNA in Melanoma-Clinic Ready?Current oncology reports · 2022
    Review
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Gabriela MarsavelaSchool of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia 6027, Australia.ORCID 0000-0002-0487-3963
Peter A JohanssonQIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4006, Australia.
Michelle R PereiraSchool of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia 6027, Australia.
Ashleigh C McEvoySchool of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia 6027, Australia.ORCID 0000-0001-5692-1317
Anna L ReidSchool of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia 6027, Australia.
Cleo RobinsonAnatomical Pathology, PathWest Laboratory Medicine, QEII Medical Centre, Nedlands, Western Australia 6009, Australia.
Lydia WarburtonSchool of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia 6027, Australia.ORCID 0000-0001-9417-1596
Muhammad A KhattakSchool of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia 6027, Australia.
Tarek M MeniawySchool of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia 6027, Australia.ORCID 0000-0002-1457-6137
Benhur AmanuelSchool of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia 6027, Australia.
Michael MillwardDepartment of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia 6010, Australia.
Nicholas K HaywardQIMR Berghofer Medical Research Institute, Herston, Brisbane, QLD 4006, Australia.
Melanie R ZimanSchool of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia 6027, Australia.ORCID 0000-0001-7527-3538
Elin S GraySchool of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia 6027, Australia.ORCID 0000-0002-8613-3570
Leslie CalapreSchool of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia 6027, Australia.
Edith Cowan University · AUQIMR Berghofer Medical Research Institute · AUThe University of Western Australia · AU

Funding

Cancer Council WA 1100249National Health and Medical Research Council 1117911
6 · The paper itself

Abstract

In this study, we evaluated the predictive value of circulating tumour DNA (ctDNA) to inform therapeutic outcomes in metastatic melanoma patients receiving systemic therapies. We analysed 142 plasma samples from metastatic melanoma patients prior to commencement of systemic therapy: 70 were treated with BRAF/MEK inhibitors and 72 with immunotherapies. Patient-specific droplet digital polymerase chain reaction assays were designed for ctDNA detection. Plasma ctDNA was detected in 56% of patients prior to first-line anti-PD1 and/or anti-CTLA-4 treatment. The detection rate in the immunotherapy cohort was comparably lower than those with BRAF inhibitors (76%,

Indexed as

BRAFcirculating tumour DNA (ctDNA)immunotherapymelanomaneoantigen loadresponsetargeted therapytumour mutational burden

Identifiers

PMID33339135
PMCPMC7765660
OpenAlexW3110725989

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.